• 1
    Hochberg MC. Systemic lupus erythematosus. Rheum Dis Clin North Am 1990; 16: 61739.
  • 2
    Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005; 32: 17068.
  • 3
    Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996; 39: 3708.
  • 4
    Esdaile J, Joseph L, Abrahamowicz M, Danoff D, Clarke A. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996; 23: 18916.
  • 5
    Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000; 39: 13169.
  • 6
    Blaese RM, Grayson J, Steinberg AD. Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 1980; 69: 34550.
  • 7
    Dixon FJ. Murine lupus: a model for human autoimmunity. Arthritis Rheum 1985; 28: 10818.
  • 8
    Jasin HE, Ziff M. Immunoglobulin synthesis by peripheral blood cells in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 21928.
  • 9
    Sakane T, Suzuki N, Takada S, Ueda Y, Murakawa Y, Tsuchida T, et al. B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988; 31: 807.
  • 10
    Hopper JE, Papagiannes E. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol 1986; 101: 12231.
  • 11
    Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972; 51: 216274.
  • 12
    Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 67380.
  • 13
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al, for the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 146773.
  • 14
    Hopper JE, Golbus J, Meyer C, Ferrer GA. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 2000; 20: 12337.
  • 15
    Hopper JE, Sequeira W, Martellotto J, Papagiannes E, Perna L, Skosey JL. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light-chain immunoglobulin. J Clin Immunol 1989; 9: 33850.
  • 16
    Dorner T, Farner NL, Lipsky PE. Ig λ and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. J Immunol 1999; 163: 102736.
  • 17
    Dorner T, Foster SJ, Farner NL, Lipsky PE. Immunoglobulin κ chain receptor editing in systemic lupus erythematosus. J Clin Invest 1998; 102: 68894.
  • 18
    Monestier M, Zouali M. Receptor revision and systemic lupus. Scand J Immunol 2002; 55: 42531.
  • 19
    Urban S, Reucher SW, Schmolke M, Hoffman U, Hiefinger-Schindlbeck R. Free light chains (FLC) of immunoglobulins as parameter resembling disease activity in autoimmune rheumatic diseases [abstract]. Ann Rheum Dis 2004; 64 Suppl 1: 141.
  • 20
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 21
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 22
    Mastroianni-Kirsztajn G, Nishida SK, Pereira AB. Are urinary levels of free light chains of immunoglobulins useful markers for differentiating between systemic lupus erythematosus and infection? Nephron Clin Pract 2008; 110: c25863.
  • 23
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 25508.
  • 24
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 25
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 26
    Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 143744.
  • 27
    Tencer J, Thysell H, Grubb A. Analysis of proteinuria: reference limits for urine excretion of albumin, protein HC, immunoglobulin G, κ- and λ-immunoreactivity, orosomucoid and α 1-antitrypsin. Scand J Clin Lab Invest 1996; 56: 691700.
  • 28
    Tencer J, Thysell H, Andersson K, Grubb A. Stability of albumin, protein HC, immunoglobulin G, κ- and λ-chain immunoreactivity, orosomucoid and α 1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest 1994; 54: 199206.
  • 29
    Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl 2004; 69: 1421.
  • 30
    Kao AH, Navratil JS, Ruffing MJ, Liu CC, Hawkins D, McKinnon KM, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 83744.
  • 31
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 46170.
  • 32
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988.
  • 33
    Ginsburg WW, Finkelman FD, Lipsky PE. Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. Clin Exp Immunol 1979; 35: 7688.
  • 34
    Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993; 177: 100920.
  • 35
    Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 237.
  • 36
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 37
    Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007; 19: 2848.
  • 38
    Solling K, Solling J, Romer FK. Free light chains of immunoglobulins in serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections and pulmonary cancer. Acta Med Scand 1981; 209: 4737
  • 39
    Nisonoff A, Hopper JE, Spring SB. The antibody molecule. New York: Academic Press; 1975.
  • 40
    Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119: 2748.
  • 41
    Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361: 48991.
  • 42
    Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 29002.
  • 43
    Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 8127.
  • 44
    Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11: 870614.
  • 45
    Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 34854.